Jess Wiggs 9/18/23 Jess Wiggs 9/18/23 Kyrgyzstan, Ukraine, and Uzbekistan Update National Guidelines for Drug-Resistant TB Treatment to Advance National Rollout of Three-Drug, Six-Month Regimen Read More Jess Wiggs 8/14/23 Jess Wiggs 8/14/23 Realizing our “Triple-A Mandate” Read More Jess Wiggs 8/10/23 Jess Wiggs 8/10/23 TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan Read More Jess Wiggs 7/26/23 Jess Wiggs 7/26/23 Pretomanid’s Addition to the WHO’s Essential Medicine List Enhances Access to All Oral, Six-Month DR-TB Therapy Read More Jess Wiggs 2/20/23 Jess Wiggs 2/20/23 Clinical Trial Results Presented at CROI 2023 Read More Jess Wiggs 12/19/22 Jess Wiggs 12/19/22 Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment Read More Jess Wiggs 12/7/22 Jess Wiggs 12/7/22 TB Alliance Receives GHTC Partnership Award for Development of Pretomanid Read More Jess Wiggs 11/16/22 Jess Wiggs 11/16/22 New Study: Recently Approved Drug-Resistant TB Treatments Can Save National Governments up to US$740 Million Annually Read More Jess Wiggs 8/31/22 Jess Wiggs 8/31/22 Drug-Resistant TB Trial Results Published in New England Journal of Medicine Read More Jess Wiggs 5/3/22 Jess Wiggs 5/3/22 TB Alliance Statement on New World Health Organization Rapid Communication on Key Changes to the Treatment of Drug-Resistant Tuberculosis Read More Jess Wiggs 3/24/22 Jess Wiggs 3/24/22 Advancing the Treatment of Drug-Resistant Tuberculosis this World TB Day Read More Jess Wiggs 10/20/21 Jess Wiggs 10/20/21 TB Alliance Welcomes New Data on BPaL-Based Regimens Presented at the 2021 Union Conference Read More Jess Wiggs 9/6/21 Jess Wiggs 9/6/21 TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB Read More Jess Wiggs 7/15/21 Jess Wiggs 7/15/21 New Trial Results Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of Linezolid Read More Jess Wiggs 3/25/21 Jess Wiggs 3/25/21 STAND Clinical Trial Results Published Read More Jess Wiggs 3/24/21 Jess Wiggs 3/24/21 TB Alliance Congratulates MSF on TB-PRACTECAL Milestone Read More Jess Wiggs 3/24/21 Jess Wiggs 3/24/21 Amid Global Pandemic, TB Treatment Innovation Advances at an Unprecedented Pace Read More Jess Wiggs 12/10/20 Jess Wiggs 12/10/20 Patients in South Africa to Access Six-Month, All-Oral Treatment for Highly Drug-Resistant Tuberculosis Read More Jess Wiggs 10/30/20 Jess Wiggs 10/30/20 TB Alliance is Honored to Accept the Prix Galien Award for Best Pharmaceutical Agent Read More Jess Wiggs 10/21/20 Jess Wiggs 10/21/20 TB Alliance with the Support of the Republic of Korea Announce Initiative to Broaden Adoption and Scale Up of New Treatments for Drug-Resistant Tuberculosis (TB) Read More Older Posts
Jess Wiggs 9/18/23 Jess Wiggs 9/18/23 Kyrgyzstan, Ukraine, and Uzbekistan Update National Guidelines for Drug-Resistant TB Treatment to Advance National Rollout of Three-Drug, Six-Month Regimen Read More
Jess Wiggs 8/10/23 Jess Wiggs 8/10/23 TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan Read More
Jess Wiggs 7/26/23 Jess Wiggs 7/26/23 Pretomanid’s Addition to the WHO’s Essential Medicine List Enhances Access to All Oral, Six-Month DR-TB Therapy Read More
Jess Wiggs 12/19/22 Jess Wiggs 12/19/22 Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment Read More
Jess Wiggs 12/7/22 Jess Wiggs 12/7/22 TB Alliance Receives GHTC Partnership Award for Development of Pretomanid Read More
Jess Wiggs 11/16/22 Jess Wiggs 11/16/22 New Study: Recently Approved Drug-Resistant TB Treatments Can Save National Governments up to US$740 Million Annually Read More
Jess Wiggs 8/31/22 Jess Wiggs 8/31/22 Drug-Resistant TB Trial Results Published in New England Journal of Medicine Read More
Jess Wiggs 5/3/22 Jess Wiggs 5/3/22 TB Alliance Statement on New World Health Organization Rapid Communication on Key Changes to the Treatment of Drug-Resistant Tuberculosis Read More
Jess Wiggs 3/24/22 Jess Wiggs 3/24/22 Advancing the Treatment of Drug-Resistant Tuberculosis this World TB Day Read More
Jess Wiggs 10/20/21 Jess Wiggs 10/20/21 TB Alliance Welcomes New Data on BPaL-Based Regimens Presented at the 2021 Union Conference Read More
Jess Wiggs 9/6/21 Jess Wiggs 9/6/21 TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB Read More
Jess Wiggs 7/15/21 Jess Wiggs 7/15/21 New Trial Results Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of Linezolid Read More
Jess Wiggs 3/24/21 Jess Wiggs 3/24/21 TB Alliance Congratulates MSF on TB-PRACTECAL Milestone Read More
Jess Wiggs 3/24/21 Jess Wiggs 3/24/21 Amid Global Pandemic, TB Treatment Innovation Advances at an Unprecedented Pace Read More
Jess Wiggs 12/10/20 Jess Wiggs 12/10/20 Patients in South Africa to Access Six-Month, All-Oral Treatment for Highly Drug-Resistant Tuberculosis Read More
Jess Wiggs 10/30/20 Jess Wiggs 10/30/20 TB Alliance is Honored to Accept the Prix Galien Award for Best Pharmaceutical Agent Read More
Jess Wiggs 10/21/20 Jess Wiggs 10/21/20 TB Alliance with the Support of the Republic of Korea Announce Initiative to Broaden Adoption and Scale Up of New Treatments for Drug-Resistant Tuberculosis (TB) Read More
